Immune Pharmaceuticals Q2 net loss $2.9 million
Article continues below
General and administrative expenses decreased by $0.4 million.
Excluding the impact of the non-operating income of $3.5 million, the net loss would have been $3.9 million in the second quarter of 2014.
Research and development expenses increased by $0.1 million during the three-month period ended June 30, 2015 to $1.1 million compared with $1.0 million during the three month period ended June 30, 2014.
General and administrative expenses decreased by $0.4 million during the three month period ended June 30, 2015 to $1.7 million, compared with $2.0 million during the three month period ended June 30, 2014.
As of June 30, 2015, the Company had 25.2 million common shares outstanding. Following the exchange and conversion of the preferred equity in July 2015, the Company had 27.1 million common shares outstanding. ■